Product category:
Chemicals and biochemicals
News Release from: Open Biosystems
Edited by the Laboratorytalk Editorial
Team on 19 June 2006
Open Biosystems responds to lawsuit
Open Biosystems responds to the lawsuit filed by Sigma-Aldrich and Oxford Biomedica alleging patent infringement, and reaffirms its commitment to the distribution of TRC lentiviral libraries
Open Biosystems says it intends to defend these claims and reaffirms its dedication to advancing scientific discoveries through the open distribution of the RNAi Consortium (TRC) lentiviral libraries "These large, publicly traded companies have targeted a privately held and socially responsible company with these accusations
This article was originally published on Laboratorytalk on 6 Dec 2001 at 8.00am (UK)
Related stories
Akcros invests in solid stabilisers
To meet growing demand for PVC stabilisers, Akcros Chemicals will invest in increased production of the Interlite ZP range of solid mixed metal soap stabilisers at its Eccles, UK, facility
MBO for Akcros
Akzo Nobel plastics and processing additives business unit, making lead stabilisers for polymer products sold, to management, and to trade under the new name Allstab
"The claims of patent infringement in the lawsuit are unfounded, and we intend to vigorously defend against them," said Troy Moore, chief technology officer, Open Biosystems.
"We conduct our business on the highest plane and in a way that results in genomic materials being made available to the research community.
"It is our belief that there is a greater value in making technologies broadly available both to the holder of the intellectual property and to the research community".
Open Biosystems continues to operate under license from the Broad Institute of MIT and Harvard, the developers of the TRC lentiviral libraries.
Sigma-Aldrich also distributes these libraries.
"It is never our policy to infringe upon intellectual property.
"Open Biosystems was founded upon an open source business model that supports basic and medical research by making the newest and best life sciences tools readily available to scientists in academia, government and industry.
"This business model is disrupting the strategy of large corporate gate-keepers that are determined to control, not advance, research efforts," said Brian Pollock, CEO of Open Biosystems.
Open Biosystems develops, manufactures and markets genomic research tools to scientists and researchers in corporate, academic and government laboratories.
These research tools provide investigators with standardised high-quality genes, RNAi and antibodies for interrogating gene function in relation to oncology, neuroscience and metabolic disorders.
Founded in 2001, Open Biosystems is headquartered in Huntsville, Alabama, USA.
• Open Biosystems: contact details and other news
• Email this article to a colleague
• Register for the free Laboratorytalk email newsletter
• Laboratorytalk Home Page
Search the Pro-Talk network of sites
